mitomycin

P2, N=40, Recruiting, Mayo Clinic | Trial completion date: May 2027 --> Jul 2029 | Trial primary completion date: May 2026 --> Jul 2029

CRS and HIPEC provide 14% 5-year survival for GCA with peritoneal metastases. Complete cytoreduction, especially with PCI < 20, improves outcomes.

This case highlights the potential role of chemoradiotherapy in managing pelvic squamous cell CUP, achieving durable remission in selected patients.

SQAP sensitized series of chemotherapeutic agents including doxorubicin, carboplatin, bleomycin, camptothecin, etoposide, methyl methanesulfonate, cisplatin, mitomycin C, and Taxol in canine tumor cells and V79 cells. These results suggest that broad inhibition of DNA repair may play a role in SQAP induced radiosensitization and chemosensitization.

This case report supports the clinical utility of pre-emptive DPYD genotyping to guide initial 5-FU dosing in intermediate metabolizers, and it suggests that all patients still require close monitoring and some (particularly carriers of c.2846 A > T) may require an initial dose reduction greater than the recommended 50% to prevent severe toxicity.

Mitomycin-C had limited activity in HPV-positive, and no activity in HPV-negative, platinum-refractory RM-HNSCC.

P3, N=220, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2027 --> Apr 2028

In addition, FANCA disruption followed by mitomycin C treatment resulted in a > 10-fold increase in chromosomal radials, a finding that is considered diagnostic for human FA...Targeting of FANCD2 failed to produce any biallelic animals demonstrating the loss of FANCD2 function is embryonic lethal in pigs. These results indicate that a porcine model of FANCA holds promise for the development of strategies to prevent the development of bone marrow failure and malignancies in patients with FA.

P2, N=76, Completed, University of Southern California | Unknown status --> Completed

HUVECs were treated with DNA crosslinkers (doxorubicin, mitomycin C), topoisomerase inhibitors (etoposide, camptothecin), and methotrexate (MTX)...ROS scavenger Mito-Q and ATM inhibitor KU55933 were co-administered to evaluate their modulatory effects...Chemotherapeutic agents triggered endothelial senescence via DNA damage and ROS accumulation, with heterogeneity in potency and mechanisms. ROS scavengers may mitigate methotrexate-associated vascular toxicity, and targeting ROS could enhance chemotherapy safety by preserving endothelial function.

P3, N=272, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

The most employed topical agents include mitomycin C (MMC), 5-fluorouracil (5-FU), and interferon alpha-2b (IFNα2b), each with distinct mechanisms of action, efficacy profiles, and toxicity risks. Timely recognition and management of complications are essential to minimize long-term sequelae. Reliance on compounded formulations highlights the need for stable, standardized, and commercially available topical agents specifically designed for ocular use to ensure safety, reproducibility, and global accessibility.